Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	100167
Country	South Korea

Received	2024-08-13 14:45
Peer-Review Started	2024-08-13 14:45
To Make the First Decision
Return for Revision	2024-11-11 07:27
Revised	2024-11-27 07:12
Second Decision	2024-12-10 02:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-10 06:15
Articles in Press	2024-12-10 06:15
Publication Fee Transferred	2024-11-28 13:35
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-17 09:07
Publish the Manuscript Online	2025-01-18 08:12

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Retrospective Study
Article Title	Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy
Manuscript Source	Unsolicited Manuscript
All Author List	Bomi Kim, Jaihwan Kim, Soomin Yang, Jinwoo Ahn, Kwangrok Jung, Jong-Chan Lee and Jin-Hyeok Hwang
Funding Agency and Grant Number
Corresponding Author	Jaihwan Kim, MD, PhD, Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Seongnam 13620, South Korea. drjaihwan@snu.ac.kr
Key Words	Pancreatic cancer; Chemotherapy; Survival; Performance status; Carbohydrate antigen 19-9
Core Tip	This study retrospectively analyzed 141 patients with advanced pancreatic cancer treated between 2012 and 2021, who underwent first-line oxaliplatin or gemcitabine plus nab-paclitaxel, followed by third-line chemotherapy. The median overall survival was 19 months, with 15.3 weeks after third-line treatment. The study identified that patients with good performance status, carbohydrate antigen 19-9 < 1000 U/mL, second-line chemotherapy ≥ 19 weeks, and no peritoneal seeding before starting third-line treatment had better outcomes regardless of the third-line regimen. These findings suggest that such patients may benefit more from third-line chemotherapy in spite of unsatisfactory treatment results from all patients.
Publish Date	2025-01-18 08:12
Citation	<p>Kim B, Kim J, Yang S, Ahn J, Jung K, Lee JC, Hwang JH. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. <i>World J Gastrointest Oncol</i> 2025; 17(2): 100167</p>
URL	https://www.wjgnet.com/1948-5204/full/v17/i2/100167.htm
DOI	https://dx.doi.org/10.4251/wjgo.v17.i2.100167

Full Article (PDF)	WJGO-17-100167-with-cover.pdf
Manuscript File	100167_Auto_Edited_083720.docx
Answering Reviewers	100167-answering-reviewers.pdf
Audio Core Tip	100167-audio.mp3
Biostatistics Review Certificate	100167-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	100167-conflict-of-interest-statement.pdf
Copyright License Agreement	100167-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	100167-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	100167-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	100167-non-native-speakers.pdf
Supplementary Material	100167-supplementary-material.pdf
Peer-review Report	100167-peer-reviews.pdf
Scientific Misconduct Check	100167-scientific-misconduct-check.png
Scientific Editor Work List	100167-scientific-editor-work-list.pdf
CrossCheck Report	100167-crosscheck-report.png
CrossCheck Report	100167-crosscheck-report.pdf